BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Reading
Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)
Slide-Kit
Nils Eckardt, Vice President Medical Affairs, Europe, shares BeiGene’s innovative vision for patients.
Video
A short summary describing a next-generation BTK inhibitor with sustained and potent activity at disease sites and low off-target kinase inhibition.
Reading
A summary from ASH 2022 addressing 12 studies on the use of BTK and Bcl-2 inhibitors for the treatment of B-cell malignancies and AML.
Slide-Kit
